NCT04673617 2026-04-03AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin LymphomaArtiva Biotherapeutics, Inc.Phase 1/2 Completed45 enrolled
NCT03666000 2026-02-02Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)Imugene LimitedPhase 1 Recruiting135 enrolled